Cognition Therapeutics(CGTX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update - CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD - - On track to report topline results from Phase 2 SHIMMER study investigating CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB) by end of 2024 - Purchase, NY – November 13, 20 ...